Mangalam Drugs & Organics Ltd
Mangalam Drugs & Organics Ltd (MANGALAM) last traded at ₹32.9, a market capitalisation of ₹52.1 crore. Over the past 52 weeks the stock has ranged between ₹22.7 and ₹86. Mangalam Drugs & Organics Ltd last reported results for the quarter ended Jun 2026, with sales of ₹57.12 crore and net profit of ₹-7.64 crore. Figures are as of 25 Aug 2026 and are not real time.
Mangalam Drugs & Organics Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Mangalam Drugs & Organics Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹57.12 cr, down 0.2% from ₹57.21 cr a year earlier. Net profit was ₹-7.64 cr, up 44.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 79.94 | 88.71 | 72.78 | 57.21 | 49.54 | 58.38 | 67.29 | 57.12 |
| Expenses | 71.24 | 79.94 | 62.88 | 61.83 | 52.38 | 59.92 | 72.91 | 56.21 |
| Operating profit | 8.7 | 8.77 | 9.9 | -4.62 | -2.84 | -1.54 | -5.62 | 0.91 |
| OPM % | 10.88% | 9.89% | 13.60% | -8.08% | -5.73% | -2.64% | -8.35% | 1.59% |
| Other income | 0.14 | 0.14 | 0.47 | 0.14 | 0.03 | 0.22 | 0.09 | 0.11 |
| Interest | 3.67 | 3.49 | 4.03 | 4.04 | 5.03 | 4.05 | 3.08 | 3.68 |
| Depreciation | 3.97 | 4.05 | 4.7 | 4.48 | 4.63 | 4.46 | 4.66 | 4.09 |
| Profit before tax | 1.2 | 1.37 | 1.64 | -13 | -12.47 | -9.83 | -13.27 | -6.75 |
| Tax % | -124.17% | 5.84% | 95.73% | 6.15% | -41.06% | 0.00% | 1.13% | 13.19% |
| Net profit | 2.69 | 1.29 | 0.06 | -13.8 | -7.35 | -9.84 | -13.42 | -7.64 |
| EPS (₹) | 1.70 | 0.82 | 0.04 | -8.72 | -4.64 | -6.22 | -8.48 | -4.83 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Mangalam Drugs & Organics Ltd annual results
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 369 | 318 | 232 | 232 |
| Operating profit | 17 | 36 | -15 | -9 |
| OPM % | 4.7% | 11% | -6% | -3.9% |
| Net profit | -9 | 7 | -44 | -38 |
| EPS (₹) | -5.73 | 4.25 | -28.05 | -24.17 |
TTM is the trailing twelve months to the most recent quarter.
Mangalam Drugs & Organics Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -22%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -292%
- 10 Years
- -16%
- 5 Years
- -26%
- 3 Years
- -33%
- 1 Year
- -62%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -12%
- Last Year
- -35%
Mangalam Drugs & Organics Ltd shareholding pattern
Promoters held 35.65% at Jun 2026, down from 50.30% at Jun 2025. FIIs 0.11%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.30% | 50.30% | 50.30% | 50.30% | 50.30% | 35.64% | 35.65% | 35.65% |
| FIIs | 0.11% | 0.11% | 0.47% | 0.53% | 0.11% | 0.13% | 0.32% | 0.11% |
| Public | 49.58% | 49.58% | 49.23% | 49.16% | 49.57% | 64.22% | 64.03% | 64.24% |
| No. of shareholders | 19,508 | 19,679 | 19,697 | 19,728 | 19,881 | 21,227 | 25,140 | 24,465 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Mangalam Drugs & Organics Ltd corporate filings
- Intimation of default under Para A sub- paragraph 6 Schedule III-subsequent defaultOthersmedium impact
Cruxal's analysis: Mangalam Drugs & Organics Ltd has filed a disclosure regarding a subsequent default under…
Read the full analysis - Newspaper publication for declaration of Un-audited Financial Results (Standalone & Consolidated) for the quarter ended 30th June, 2026Company Updatehigh impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has reported a sharp deterioration in financial…
Read the full analysis - Outcome of Board meeting held on 12th August, 2026 interalia for approval of Un-Audited Financial results (Standalone & Consolidated) for the quarter ended 30th June, 2026Board Meetinghigh impact
Cruxal's analysis: Mangalam Drugs and Organics Limited reported a standalone net loss of 7.55 crore for the…
Read the full analysis - Intimation pursuant to Regulation 30 read with Schedule III of SEBI (LODR), Regulations, 2015 regarding resiagntion tendered by Ragini Chokshi & Co., Secretarial Auditor of the Company ....Company Updatelow impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has informed the stock exchanges that M/s. Ragini…
Read the full analysis - Mangalam Drugs & Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Prior Intimation ....Board Meetinglow impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has issued a formal intimation regarding a Board…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Mangalam Drugs & Organics Ltd
Cruxal reads every Mangalam Drugs & Organics Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.